In consultation: Guidance and quality standards
Showing 11 to 17 of 17
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Oveporexton for treating type 1 narcolepsy [ID6622] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Ruxolitinib for treating moderate atopic dermatitis ID6602 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| NICE-wide Topic Prioritisation: the manual (PMG46) 2026 Update Consultation | Methods / process manual consultation | NICE process and methods | |
| Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409] | Draft guidance | Technology appraisal guidance | |
| Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374] | Final draft guidance | Technology appraisal guidance | |
| Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] | Final draft guidance | Technology appraisal guidance | |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Final draft guidance | Technology appraisal guidance |